Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jinhong Gong, Jingjing Shang, Dan Su, Xiaodan Qian, Guangjun Liu & Zhiqiang Sun. (2023) Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research 23:6, pages 709-717.
Read now
Read now
Lukas J. Meier, Alice Hein, Klaus Diepold & Alena Buyx. (2022) Algorithms for Ethical Decision-Making in the Clinic: A Proof of Concept. The American Journal of Bioethics 22:7, pages 4-20.
Read now
Read now
Sabine Vogler. (2021) Can we achieve affordable cancer medicine prices? Developing a pathway for change. Expert Review of Pharmacoeconomics & Outcomes Research 21:3, pages 321-325.
Read now
Read now
R. Andrew Harkins & Christopher R. Flowers. (2020) How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?. Leukemia & Lymphoma 61:14, pages 3283-3286.
Read now
Read now
Paolo Vercellini, Maria Pina Frattaruolo & Laura Buggio. (2018) Toward minimally disruptive management of symptomatic endometriosis: reducing low-value care and the burden of treatment. Expert Review of Pharmacoeconomics & Outcomes Research 18:1, pages 1-4.
Read now
Read now
Articles from other publishers (50)
Alene Sze Jing Yong, Ka Keat Lim, Julia Fox-Rushby, Fuad Ismail, Ednin Hamzah, Mark Wing Loong Cheong & Siew Li Teoh. (2023) A Longitudinal Evaluation of the Preferences of Patients With Advanced Cancer for Quality of Life and Survival in Malaysia: A Discrete Choice Experiment. Value in Health 26:12, pages 1772-1781.
Crossref
Crossref
Jenna Smith-Turchyn, Julie Richardson, Susanne Sinclair, Ying Xu, Silvana Choo, Janelle Gravesande, Aiping Lai, Elyse Letts, Muhib Masrur, Ashley Morgan, Celeste Petrusevski, Holly Edward & Feng Xie. (2023) Cost Effectiveness of Physiotherapy Services for Chronic Condition Management: A Systematic Review of Economic Evaluations Conducted Alongside Randomized Controlled Trials. Physiotherapy Canada.
Crossref
Crossref
Lijoy Varghese, Weiqin Lin, Stephan Linden, Ai Ling Lum & David Sim. (2023) Cost-Effectiveness of Empagliflozin on Top of Standard of Care for Heart Failure With Reduced Ejection Fraction in Singapore. Value in Health Regional Issues 34, pages 108-117.
Crossref
Crossref
N. D. Clement, S. Radha, I. Afzal, B. Gurung, V. Asopa, N. Caplan & D. Kader. (2022) Factors associated with a clinically significant improvement in health-related quality of life after total knee arthroplasty. European Journal of Orthopaedic Surgery & Traumatology 33:6, pages 2505-2514.
Crossref
Crossref
Elena Keller & Georgina M. Chambers. (2022) Valuing infertility treatment: Why QALYs are inadequate, and an alternative approach to cost-effectiveness thresholds. Frontiers in Medical Technology 4.
Crossref
Crossref
Edward R. Scheffer Cliff & Ankur Pandya. (2022) Pola-R-CHP for DLBCL: cost-effective at first glance. Blood 140:25, pages 2654-2655.
Crossref
Crossref
Louise Biddle, Katharina Wahedi & Kayvan Bozorgmehr. (2022) Comparable worth of life for all? Conducting and disseminating health economic evaluations for refugees in Germany. Globalization and Health 18:1.
Crossref
Crossref
Wanrudee Isaranuwatchai, Ryota Nakamura, Hwee Lin Wee, Myka Harun Sarajan, Yi Wang, Budsadee Soboon, Jing Lou, Jia Hui Chai, Wannisa Theantawee, Jutatip Laoharuangchaiyot, Thanakrit Mongkolchaipak, Thanisa Thathong, Pritaporn Kingkaew, Kriang Tungsanga & Yot Teerawattananon. (2022) What are the impacts of increasing cost-effectiveness Threshold? a protocol on an empirical study based on economic evaluations conducted in Thailand. PLOS ONE 17:10, pages e0274944.
Crossref
Crossref
Andreas Albertsen. (2022) Rare diseases in healthcare priority setting: should rarity matter?. Journal of Medical Ethics 48:9, pages 624-628.
Crossref
Crossref
Joost J. Enzing, Saskia Knies, Jop Engel, Maarten J. IJzerman, Beate Sander, Rick Vreman, Bert Boer & Werner B. F. Brouwer. (2022) Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports. Cost Effectiveness and Resource Allocation 20:1.
Crossref
Crossref
Nick D. Clement, Irrum Afzal, Christian J. H. Peacock, Deborah MacDonald, Gavin J. Macpherson, James T. Patton, Vipin Asopa, David H. Sochart & Deiary F. Kader. (2022) Mapping analysis to predict the associated EuroQol five-dimension three-level utility values from the Oxford Knee Score. Bone & Joint Open 3:7, pages 573-581.
Crossref
Crossref
Alyssa Bilinski, Evan MacKay, Joshua A. Salomon & Ankur Pandya. (2022) Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists. Value in Health 25:7, pages 1141-1147.
Crossref
Crossref
Howard Cuckle, Seppo Heinonen, Anna-Kaisa Anttonen & Vedran Stefanovic. (2022) Cost of providing cell-free DNA screening for Down syndrome in Finland using different strategies. Journal of Perinatal Medicine 50:3, pages 233-243.
Crossref
Crossref
Victoria Charlton. (2022) The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies. Health Economics, Policy and Law, pages 1-27.
Crossref
Crossref
Lucca Katrine Sciera, Lars Frost, Lars Dybro & Peter Bo Poulsen. (2022) The cost-effectiveness of one-time opportunistic screening for atrial fibrillation in different age cohorts of inhabitants in Denmark aged 65 years and above: a Markov modelled analysis. European Heart Journal - Quality of Care and Clinical Outcomes 8:2, pages 177-186.
Crossref
Crossref
NAC van den Boom, AA van den Hurk, PHS Kalmet, M Poeze & SMAA Evers. (2022) Economic evaluations in fracture research an introduction with examples of foot fractures. Injury 53:3, pages 895-903.
Crossref
Crossref
Hoong Sern Lim, Steven Shaw, Alexander W. Carter, Sahan Jayawardana, Elias Mossialos & Mandeep R. Mehra. (2022) A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: A United Kingdom perspective. The Journal of Heart and Lung Transplantation 41:2, pages 174-186.
Crossref
Crossref
Thomas Ward, Ruben E. Mujica-Mota, Anne E. Spencer & Antonieta Medina-Lara. (2021) Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review. PharmacoEconomics 40:1, pages 45-64.
Crossref
Crossref
Wen‐Cheng Chang, Amy Y. Lin, Jason C. Hsu, Chiao‐En Wu, Connie Goh, Patrick Chou, Kaitlin Kuo, Anne Chang & Roberto Palencia. (2021) A cost‐utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan. Cancer Reports 4:6.
Crossref
Crossref
Mac Ardy Junio Gloria, Montarat Thavorncharoensap, Usa Chaikledkaew, Sitaporn Youngkong, Ammarin Thakkinstian & Anthony J. Culyer. (2021) A Systematic Review of Demand-Side Methods of Estimating the Societal Monetary Value of Health Gain. Value in Health 24:10, pages 1423-1434.
Crossref
Crossref
Wolfgang Greiner, Keyur Patel, Christina-Jane Crossman-Barnes, Troels Vingtoft Rye-Andersen, Christian Hvid & Tom Vandebrouck. (2021) High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?. PharmacoEconomics - Open 5:3, pages 385-396.
Crossref
Crossref
Bettina M. Zimmermann, Johanna Eichinger & Matthias R. Baumgartner. (2021) A systematic review of moral reasons on orphan drug reimbursement. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Anton L. V. Avanceña, David W. Hutton, Josie Lee, Kurt R. Schumacher, Ming‐Sing Si & David M. Peng. (2021) Cost‐effectiveness of implantable ventricular assist devices in older children with stable, inotrope‐dependent dilated cardiomyopathy. Pediatric Transplantation 25:4.
Crossref
Crossref
Marc A. Rodwin. (2021) How the United Kingdom Controls Pharmaceutical Prices and Spending: Learning From Its Experience. International Journal of Health Services 51:2, pages 229-237.
Crossref
Crossref
Ting-An Tai, Nicholas R. Latimer, Ágnes Benedict, Zsofia Kiss & Andreas Nikolaou. (2021) Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making. Value in Health 24:4, pages 505-512.
Crossref
Crossref
Leonie Segal. (2021) A Big WIN in Texas: Demonstrating the Benefits of Patient Self-Efficacy and Patient Activation. Value in Health 24:3, pages 344-345.
Crossref
Crossref
Nicholas M. Selby, Luís Korrodi-Gregório, Anna Casula, Nitin V. Kolhe, Daniel Ribes Arbonés, Katelyn D. Bukieda, Deepak Sahu, Chris Rao & Giacomo Basadonna. (2021) Randomized Controlled Trial Evidence of Cost-Effectiveness of a Multifaceted AKI Intervention Approach. Kidney International Reports 6:3, pages 636-644.
Crossref
Crossref
Darius N. Lakdawalla & Charles E. Phelps. (2021) Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach. Value in Health 24:2, pages 244-249.
Crossref
Crossref
David SP Tan, Jack Junjie Chan, Robert Hettle, Wrik Ghosh, Amrita Viswambaram & Cindy Chen Yu. (2021)
Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with
BRCA
-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
. Journal of Gynecologic Oncology 32:2.
Crossref
Crossref
Nadine T. Hillock, Tracy L. Merlin, Jonathan Karnon, John Turnidge & Jaklin Eliott. (2020) Value assessment of antimicrobials and the implications for development, access, and funding of effective treatments: Australian stakeholder perspective. International Journal of Technology Assessment in Health Care 37:1.
Crossref
Crossref
Anton L.V. Avanceña & Lisa A. Prosser. (2021) Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review. Value in Health 24:1, pages 136-143.
Crossref
Crossref
Sarah Dewilde, Kevin Carroll, Emilia Nivelle & James Sawyer. (2020) Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective. Cost Effectiveness and Resource Allocation 18:1.
Crossref
Crossref
Shilpa Gupta & Ashish M. Kamat. (2020) NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?. Nature Reviews Urology 17:9, pages 491-492.
Crossref
Crossref
Mike Paulden. (2020) Why it’s Time to Abandon the ICER. PharmacoEconomics 38:8, pages 781-784.
Crossref
Crossref
Massimo Bilancia, Giuseppe Pasculli & Danilo Di Bona. (2020) A non-stationary Markov model for economic evaluation of grass pollen allergoid immunotherapy. PLOS ONE 15:5, pages e0232753.
Crossref
Crossref
Inhae Park, Jesse Gale & Simon E. Skalicky. (2020) Health Economic Analysis in Glaucoma. Journal of Glaucoma 29:4, pages 304-311.
Crossref
Crossref
Kai Huter. (2020) Gerechtigkeit in der gesundheitsökonomischen Evaluation von Public Health – Überblicksartikel. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 150-152, pages 80-87.
Crossref
Crossref
Irina V. Mikheeva & Marina A. Mikheeva. (2020) Cost-Effectiveness Analysis of Revaccination Against Pertussis in Preschool Children. Current Pediatrics 18:6, pages 470-477.
Crossref
Crossref
Filippo Ansaldi, Sarah Pugh, Daniela Amicizia, Roberto Di Virgilio, Cecilia Trucchi, Andrea Orsi, Alessandro Zollo & Giancarlo Icardi. (2020) Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy. Pathogens 9:2, pages 76.
Crossref
Crossref
Scott C Bell, Marcus A Mall, Hector Gutierrez, Milan Macek, Susan Madge, Jane C Davies, Pierre-Régis Burgel, Elizabeth Tullis, Claudio Castaños, Carlo Castellani, Catherine A Byrnes, Fiona Cathcart, Sanjay H Chotirmall, Rebecca Cosgriff, Irmgard Eichler, Isabelle Fajac, Christopher H Goss, Pavel Drevinek, Philip M Farrell, Anna M Gravelle, Trudy Havermans, Nicole Mayer-Hamblett, Nataliya Kashirskaya, Eitan Kerem, Joseph L Mathew, Edward F McKone, Lutz Naehrlich, Samya Z Nasr, Gabriela R Oates, Ciaran O'Neill, Ulrike Pypops, Karen S Raraigh, Steven M Rowe, Kevin W Southern, Sheila Sivam, Anne L Stephenson, Marco Zampoli & Felix Ratjen. (2020) The future of cystic fibrosis care: a global perspective. The Lancet Respiratory Medicine 8:1, pages 65-124.
Crossref
Crossref
James F. O’Mahony & Mike Paulden. (2019) The Joint Committee on Vaccination and Immunisation’s Advice on Extending Human Papillomavirus Vaccination to Boys: Were Cost-Effectiveness Analysis Guidelines Bent to Achieve a Politically Acceptable Decision?. Value in Health 22:11, pages 1227-1230.
Crossref
Crossref
Øystein Ariansen Haaland, Frode Lindemark & Kjell Arne Johansson. (2019) A flexible formula for incorporating distributive concerns into cost-effectiveness analyses: Priority weights. PLOS ONE 14:10, pages e0223866.
Crossref
Crossref
Ash Bullement, Paul Nathan, Anna Willis, Amerah Amin, Cameron Lilley, Ceilidh Stapelkamp, Anthony Hatswell, Chris Pescott & Murtuza Bharmal. (2019) Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma. PharmacoEconomics - Open 3:3, pages 377-390.
Crossref
Crossref
Setti Raïs Ali & Sandy Tubeuf. (2019) (In)-Equality in the Allocation of R&D Resources for Rare Diseases. Social Justice Research 32:3, pages 277-317.
Crossref
Crossref
Sean P. Gavan, Christine Y. Lu & Katherine Payne. (2019) Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies. Journal of Personalized Medicine 9:2, pages 28.
Crossref
Crossref
James F. O'Mahony & Mike Paulden. (2019) Appraising the cost-effectiveness of vaccines in the UK: Insights from the Department of Health Consultation on the revision of methods guidelines. Vaccine 37:21, pages 2831-2837.
Crossref
Crossref
L Alio, S Angioni, S Arena, L Bartiromo, V Bergamini, N Berlanda, C Bonin, M Busacca, M Candiani, G Centini, M N D’Alterio, A Di Cello, C Exacoustos, L Fedele, M P Frattaruolo, D Incandela, L Lazzeri, S Luisi, A Maiorana, F Maneschi, F Martire, C Massarotti, A Mattei, L Muzii, J Ottolina, A Perandini, F Perelli, I Pino, M G Porpora, D Raimondo, V Remorgida, R Seracchioli, E Solima, E Somigliana, G Sorrenti, R Venturella, P Vercellini, P Viganó, M Vignali, F Zullo & E Zupi. (2019) When more is not better: 10 ‘don’ts’ in endometriosis management. An ETIC* position statement. Human Reproduction Open 2019:3.
Crossref
Crossref
Shirin Rizzardo, Nick Bansback, Nick Dragojlovic, Conor Douglas, Kathy H. Li, Craig Mitton, Carlo Marra, Litsa Blanis & Larry D. Lynd. (2019) Evaluating Canadians’ Values for Drug Coverage Decision Making. Value in Health 22:3, pages 362-369.
Crossref
Crossref
Thomas G. Poder. (2018) Challenges to make cost-effectiveness studies usable by decision makers. The Journal of Thoracic and Cardiovascular Surgery 156:5, pages 1931-1932.
Crossref
Crossref
James Shearer, Sarah Byford & Steve Birch. (2017) REFLECTIONS ON THE NICE DECISION TO REJECT PATIENT PRODUCTION LOSSES. International Journal of Technology Assessment in Health Care 33:6, pages 638-643.
Crossref
Crossref